Patients with breast cancer (BrCa) brain metastases (BrM) have limited therapeutic options. A better understanding of molecular alterations acquired in BrM could identify clinically actionable metastatic dependencies.
negative BrM, no targeted therapies have shown even modest benefits. 3 In this study, we performed targeted expression profiling on a molecularly diverse cohort of 20 primary breast tumors and their patient-matched BrM to determine transcriptional differences between primary cancers and BrM and to define metastasis-acquired alterations that may be clinically actionable.
Methods
Eligible BrCa cases harbored paired formalin-fixed, paraffinembedded tissue from primary BrCa and resected BrM (eTable 1inSupplement 1). Two independent data sets reinforced findings-17 patient-matched BrCa cases of whole-exome sequencing data 4 and targeted sequencing from 7884 BrCa tumors enriched for metastases. This study was approved by the institutional review boards of both participating institutions. NanoString expression counts for target genes were generated from tumor RNA extracts. Hierarchical clusters, PAM50/ Oncotype DX assignments, 5 and fold-change expression values between patient-matched tumors (eFigure 1 in Supplement 1) were called using normalized expression counts. Standard clinical ERBB2/HER2 and estrogen receptor (ER) immunohistochemistry (IHC) analyses were performed. DNA from case Pitt_62 was extracted and analyzed for ERBB2 gains using a single-nucleotide polymorphism-based microarray. Metastasis-specific ERBB2/HER2 copy number alteration and single-nucleotide variation (SNV) gains in whole-exome sequencing were interrogated with CNVkit and GATK. 6, 7 To test for site-specific enrichment of ERBB2/HER2 amplifications and SNVs in metastases, we analyzed FoundationOne (Foundation Medicine) targeted sequencing data. More detailed methods can be found in Supplement 1, and more detailed results, including unprocessed raw count data, can be found in Supplement 2.
Results
To determine the transcriptional similarity between primary tumors and patient-matched BrM, we performed unsupervised hierarchical clustering on normalized gene expression values. This produced 3 major clades broadly classified as ERpositive, ERBB2/HER2-positive, and ER-negative ( Figure 1A) . Overall, 12 of 20 (65%) patient-matched pairs clustered within a single doublet clade. PAM50 assignments were concordant in 17 of 20 pairs ( Figure 1B ). OncotypeDX (Genomic Health) scores were also largely unchanged between primary and metastatic tumors, retaining their clinical risk score in 15 of 20 cases (eTable 2 in Supplement 1).
Despite a large degree of similarity between patientmatched pairs, 100 genes were recurrently altered (eFigure 2A in Supplement 1); 55 genes harbored 2-fold expression gains and/or losses in at least 25% of cases ( Figure 2A) . The most recurrently down-regulated genes were cytokeratins-KRT17 in 14 of 20 pairs, KRT5 and KRT14 in 15 pairs (eFigure 2B in Supplement 1). The most recurrently up-regulated genes were RAB6B and GRB7 (eFigure 2B in Supplement 1).
Ten genes in the panel are defined as clinically actionable, 8 and all but 3 cases had at least 1 gene with a BrM-specific change ( Figure 2B ). ERBB2/HER2 was the most recurrent alteration showing at least a 2-fold expression increase in 35% of BrM. Notably, 3 cases were classified as ERBB2/HER2-negative in the primary tumor. FGFR4 showed increased expression in 30% of BrM, with 3 cases showing a greater than 4-fold increase.
Other recurrent gains included FLT1, AURKA, and EGFR. The most recurrently down-regulated gene was ESR1, showing a 2-fold expression decrease in 4 samples and a greater than 4-fold decrease in 5 samples. Two samples with the greatest fold-change in ESR1 switched expression from ER-positive to ER-negative levels, with 1 case showing substantial protein level changes (eFigure 3A and B in Supplement 1). ERBB2/HER2 IHC was performed in 3 ERBB2/HER2-negative samples with the greatest mRNA gains in ERBB2/ HER2 ( Figure 3A) . All 3 tumors showed clinical ERBB2/HER2-status switching via IHC scores-RCS_4 and RCS_6; 1+ in primary, 3+ in BrM (data not shown), Pitt_62; 0 in primary, 3+ in BrM (eFigure 4A in Supplement 1). Single-nucleotide polymorphism array copy number alteration analysis revealed that ERBB2/HER2 status switching is driven by canonical amplification of the ERBB2/HER2 locus (eFigure 4B in Supplement 1).
Given that 3 of 13 ERBB2/HER2-negative tumors showed ERBB2/HER2 gains, we then examined ERBB2/HER2 amplification and SNVs in an independent whole-exome sequencing cohort (n = 17; 9 ERBB2/HER2-negative and 8 ERBB2/HER2-positive) of patient-matched cases (dbGaP phs000730.v1.p). 9 One ERBB2/HER2-negative case (Broad_PB0150) showed a metastasis-specific copy number gain in ERBB2/HER2, which was consistent with the case switching to ERBB2/HER2-positive clinically in the BrM (eFigure 5 in Supplement 1). Another case (Broad_PB0049) switched from ERBB2/HER2-negative to
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Question Do brain metastases gain clinically actionable molecular alterations when compared with patient-matched primary breast cancers?
Findings Overall, 17 of 20 brain metastases in this study retained the PAM50 subtype of the primary tumor; yet, clinically actionable gains are common, with approximately 20% of ERBB2/HER2-negative primary tumors switching to ERBB2/HER2-positive.
Meaning Breast cancer brain metastases commonly acquire alterations in clinically actionable genes, which has immediate clinical implications and supports comprehensive profiling of metastases to inform clinical care. 
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Breast Cancer Brain Metastases and ERBB2/HER2 Activating Mutations ERBB2/HER2-positive clinically, but no metastasis-specific copy number alteration gain was appreciated within ERBB2/ HER2; however, an enrichment-from an allele frequency of 39% to 69%-of a somatic V777L activating mutation in the metastasis was identified (eFigure 5 in Supplement 1).
To generalize these observations and test whether ERBB2/ HER2 gains are enriched in BrM, we analyzed a cohort of 7884 breast cancers (7265 with unambiguous tissue site information) representing 3135 cases of local disease and 4130 cases of metastases for amplifications and/or SNV in ERBB2/HER2. Comparing all local and metastatic tumors from all sites ( Figure 3B ) showed no significant difference; however, there was a strong and significant enrichment of ERBB2/HER2 alterations specifically in brain metastases (24%) compared with local disease (13%) (Fisher exact P < .001) ( Figure 3B ).
Discussion
The brain is a common and catastrophic site of metastasis for patients with breast cancer and an understanding of metastasis-acquired alterations is limited. In this study, we found that patient-matched primary BrCa and BrM have similar intrinsic subtypes; however, when examining on a gene level, clinically actionable alterations were identified in all but 3 pairs.
The most recurrent gain in BrM was ERBB2/HER2, which showed expression increases in 7 of 20 (35%) of BrM and changes from ERBB2/HER2-negative to ERBB2/HER2-positive levels. Duchnowska et al 10 and Thomson et al 11 reported ERBB2/HER2-negative to ERBB2/HER2-positive switching frequencies of 16% and 18% respectively in BrM via IHC. Pitt_72  RCS_1  RCS_2  RCS_3  RCS_4  RCS_5  RCS_6   85%  80%  75%  65%  60%  55%  55%  55%  50%  50%  50%  50%  50%  50%  50%  45%  45%  45%  45%  45%  45%  45%  45%  40%  40%  40%  40%  40%  40%  35%  35%  35%  35%  35%  35%  30%  30%  30%  30%  30%  30%  30%  30%  30%  25%  25%  25%  25%  25%  25%  25%  25%  25%  25%  25%   KRT17  KRT5  KRT14  WISP1  MMP9  MGP  PGR  ESR1  RAB6B  LOC100288906  HOXB13  STC2  NMU  PALM2  CEGP1  GRB7  AZGP1  FGFR4  ZNF533  CDH3  RBBP8  IGFBP5  MIA  MAPT  COL4A2  HRASLS  ESM1  CD68  MMP11  ERBB2  NAT1  CTSL2  CENPA  AKAP2  MS4A7  GAPDH  MLPH  DIAPH3  SLC2A3  FLT1  UBE2T  GSTM1  MYC  TGFB3  PHGDH  EXO1  OXCT1  RASSF7  CDCA7  EBF4  EGFR  FOXA1  JHDM1D LGP2 PRC1 reinforces these observations and shows expression gains are partially driven by classical amplification of the ERBB2 locus. Interestingly, the ERBB2/HER2-switching Broad_PB0049 case showed no copy number gains specific to the BrM, yet harbored an enrichment of the activating V777L ERBB2/HER2 mutation, 13 suggesting another DNA-level mechanism of ERBB2/HER2 gain in BrM. Novel recurrent targetable alterations beyond ERBB2/ HER2 were also discovered, including expression increases in FGFR4 (30% of pairs), FLT2 (20%), AURKA (10%) and EGFR (10%). Each one of these targets have clinical trials ongoing and our results suggest that trial eligibility requiring expression of these markers (NCT02325739) should assess metastatic tumors if available, especially given greater than 4-fold mRNA expression gains over primary tumors in patient-matched metastases. A limitation of this study, however, is the small number of patient-matched pairs.
Figure 2. Recurrent Expression Alterations in Breast Cancer Brain Metastases
Significant loss of gene expression from the primary to metastatic lesions was also observed. The most recurrent expression losses involved cytokeratins. Cytokeratins have shown a complex role in oncogenesis and breast cancer metastasis, with loss of cytokeratin expression being a hallmark of epithelial-mesenchymal transition and metastasis. 14, 15 Intermediate steps of metastasis-such as processes taking place within circulating tumor cells-may be masked in our paired analyses. The most recurrently lost clinically actionable gene was ESR1. Importantly, loss of ER expression is an established mediator of therapy resistance. 16 
Conclusions
Breast cancer BrM are remarkably similar transcriptionally to patient-matched primary tumors; yet, recurrent expression changes in clinically actionable genes are common. Given this evolution, metastasis-acquired features should inform targeted therapy selection and trial eligibilities in advanced cancer settings. Furthermore, approximately 20% of ERBB2/HER2-negative patients with BrCa show copy number alteration and/or SNV gains in ERBB2/HER2 across multiple cohorts, which warrants immediate clinical attention as many of these patients will not be provided ERBB2/HER2-targeted therapies. Tissue Processing. Formalin-fixed paraffin-embedded (FFPE) tumor blocks were sectioned and H&E staining analyzed by a pathologist (PCL) for histological and tumor cellularity classifications. All specimens had a tumor cellularity equal to or above 60% except for BM_Pitt_68 (40%) and BM_Pitt_71 (30%). Between four to ten (depending on tumor size) 10-micron FFPE sections immediately adjacent to the H&E-analyzed section were scrolled and pooled for dual DNA/RNA extraction using Qiagen's AllPrep kit according to manufacturer's instructions.
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NanoString and RNA expression. Samples were analyzed using a NanoString codeset consisting of probes for 141 genes (127 target, 14 housekeeping) as previously reported (Data Supplement S1) 2 .
Clustering and Molecular Subtyping. Hierarchical clustering was performed on normalized expression data (Data Supplement S2, S3). Clustering was performed using the hclust function in R, with 1 minus Pearson correlation as distance measures and the "average" agglomeration method. Heatmap was created with heatmap.3 in R. PAM50 molecular subtyping was performed using genefu 3 . To account for PAM50 test set bias 4 , normalized expression data from a cohort of 20 tumor samples with known ER-status were subsampled to create a balanced cohort of ER-positive and ER-negative tumors. A query sample of unknown molecular subtype was added to the balanced cohort. Expression data was then median centered and an intrinsic molecular subtype was called for the query sample using the pam50.robust model in genefu. This method was repeated for all 40 clinical specimens (Data Supplement S4). OncoTypeDX scores were determined using unscaled genefu OncoTypeDX scores and a linear model generated from 72 samples with known OncoTypeDX scores as performed previously 2 .
Recurrent expression alterations and clinically actionable genes. An 'expression alteration' was defined as a 2-fold change in normalized expression counts (Data Supplement S5). This threshold was chosen because the mean log2 fold-change between primary and metastatic lesions for all genes across all samples was -0.01 with a standard deviation of 1.04 (i.e. approximately a 2-fold change). Recurrent alterations were plotted using ComplexHeatmap
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. To interrogate clinically significant alterations, the Drug-Gene Interaction (DGIdb 2.0) database was used 6 . All genes were input into the database and only those annotated as 'clinically actionable' (as of March 10 th , 2016) were visualized.
To plot and statistically assess gene-specific expression differences, the beeswarm R package was used to create ladder plots along with Wilcoxon signed-rank tests on paired (primary vs. metastasis) normalized log2 expression values.
IHC Staining. 10 micron FFPE sections were mounted on slides and stained for HER2 and ER as described previously 7 .
Copy number variation (CNV) and Single Nucleotide Variant (SNV) Analysis. Tumor DNA quality was assessed by an Illumina FFPE QC Kit. DNA with a Delta Cq value below 5 were restored using the Infinium HD FFPE DNA Restore Kit. 200 ng of restored tumor DNA was ran on an Illumina iScan System using an Illumina HumanCytoSNP-FFPE v.2.1 BeadChip. GenomeStudio was implemented to produce normalized logR intensity values from the two-color readouts using the HumanCytoSNP-12v2.1-FFPE_G.egt cluster file. These values were then analyzed using the copynumber package in R 8 . LogR values were preprocessed by excluding outliers via Winsorization and imputing missing measurements as a logR value of 0. Data then underwent multi-sample segmentation and final LogR values and segments were assessed and plotted for chromosome 17 (Data Supplement S6). Raw fastq files from whole-exome sequencing of an independent cohort of 17 patient-matched primary BrCa and BrM were aligned using bwa (v0.7.13), sorted with samtools (v1.3), duplicates marked and removed with picardtools (v1.140) and local realignment performed with GATK (v3.4-46) [9] [10] [11] . To estimate and plot logR ratios, CNVkit was utilized on processed bam files 12 . A pool of bam files from normal tissue was used as a CNVkit reference. Log2 ratio estimates were then analyzed for metastasis-specific gains in ERBB2 by performing a student's t-test on primary and metastatic estimated logR values across the 26 ERBB2 exonic regions (Data Supplement S7). To discover ERBB2 activating mutations in the HER2-switching PB0049 case, the ERBB2 region was probed for somatic mutations using CLC Genomics Workbench (http://www.clcbio.com, v9.0) and IGV (v2.3.60) 13 .
FoundationOne ERBB2 Alterations. To test whether ERBB2 amplification and base pair mutation is metastasis-site specific, changes in this gene were evaluated in an expanded cohort of 7,884 breast tumors enriched for metastatic samples (52%) including liver (16.7%), lung (4.3%), bone (3.6%), and brain (2.0%) that underwent genomic profiling as part of routine clinical care in a CLIA-certified, CAP-accredited, and New York State-accredited laboratory 14 . ERBB2 alterations were identified as described previously 14, 15 . ERBB2 alteration types and frequencies in local breast cancer tumors and brain metastasis can be found in Data Supplement S8. Top; Broad PB0150 CNVkit LogR plots from primary and brain metastasis. Segmented LogR ratio means are marked with horizontal orange lines across a 4 MB region surrounding the ERBB2 locus (designated with a vertical yellow line). Bottom; PB0049 V777L activating ERBB2 mutation in primary and brain metastasis as visualized in IGV. G to C variant highlighted in blue, along with variant frequency barplots above.
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